Page 6,604«..1020..6,6036,6046,6056,606..6,6106,620..»

See Autism activist Temple Grandin speak

Posted: Published on August 13th, 2012

LITTLE ROCK, (Ark,)- Temple Grandin, Ph.D., diagnosed with autism at the age of 2, overcame social disdain and uncooperative educators to become one of the nation's leading experts in the treatment of livestock as well as an outspoken activist in the field of autism. Grandin's story, a source of inspiration worldwide for those with autism and their family members, will be the focus of her presentation at a luncheon Aug. 13 at the Arkansas Governor's Mansion. Tickets for the luncheon are $40 and can be purchased by contacting Renie Rule, (501) 526-4232 or RPRule@uams.edu. Named one of Time magazine's "100 Most Influential People in the World" in 2010, she received a master's degree in animal science from Arizona State University in 1975, and a doctoral degree in animal science from the University of Illinois at Urbana-Champaign in 1989. The HBO film about her life and early career, "Temple Grandin," earned five Emmys in 2010. The event is sponsored by the University of Arkansas for Medical Sciences' Psychiatric Research Institute and the UAMS College of Medicine's Division of Genetics, and hosted by honorary co-chairs Clarke Delp, Victor Jacuzzi, Dorothy Morris, and Carrie and Miles Eggart. The luncheon will include a panel … Continue reading →

Comments Off on See Autism activist Temple Grandin speak

Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine …

Posted: Published on August 13th, 2012

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (ACOR) today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis (MS). The study failed to confirm efficacy of the 5mg dose. The study randomized 430 participants across three treatment arms: placebo, 5 mg or the currently marketed dose of 10 mg of dalfampridine-ER, twice daily. Baseline characteristics were measured at a single visit after randomization, following a qualifying screening visit. Study drug was then given for 4 weeks. Participants returned after 2 weeks on study drug for interim measurements (Visit 2), and again at 4 weeks (Visit 3). The primary outcome was the change in walking speed (feet/second) on the Timed 25-Foot Walk (T25FW) test at Visit 3, measured at the time of peak plasma drug concentration, versus baseline. Improvements in the primary outcome for the 5 mg dose (0.423 ft/sec, p=0.457) and the 10 mg dose (0.478 ft/sec, p=0.107) at Visit 3 were not statistically significant compared to placebo (0.363 ft/sec). The AMPYRA (dalfampridine) Extended Release Tablets, 10 mg registration studies used a consistent response analysis to allow for the variability in MS-related symptoms, including walking ability. The … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine …

InVivo Therapeutics Neurosurgeon Receives MDHonors Grant For Applying Hydrogels to Spinal Cord Injury

Posted: Published on August 13th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, announced today that one of the companys neurosurgeons, Amer Khalil, MD, has been selected as the winner of an MDH Research Award, a grant given by MDHonors, to further InVivos research on spinal cord injury. Dr. Khalil was awarded a grant of $10,000 for his project titled Spinal cord repair using biomaterial-based drug-releasing strategies for reducing scarring and promoting regeneration. Dr. Khalils project is important not only for InVivos second SCI product but also for the third product in the companys portfolio, a platform intended for the reduction of fibrosis which has been developed to reduce scarring in both reparative surgical and dermatological applications. Combining the need for minimizing scarring after reparative surgery and the fast growing market demand for minimizing scarring following plastic surgery procedures, InVivo believes that this technology will result in millions of treatments per day in the U.S., and the company intends to lead the space. Amer has contributed to our team for over a year now, and were proud to see his peer researchers acknowledge what we see every day at InVivo, … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Neurosurgeon Receives MDHonors Grant For Applying Hydrogels to Spinal Cord Injury

Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson's diseases

Posted: Published on August 13th, 2012

Public release date: 13-Aug-2012 [ | E-mail | Share ] Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice. Latrepirdine was initially sold as an antihistamine in Russia, following its approval for use there in 1983. In the 1990s, the compound appeared effective in treating some of the earliest animal models of Alzheimer's disease. In a high profile Phase II clinical trial in Russia, overseen by a panel of top U.S. clinical trial experts, including Mount Sinai's Mary Sano, PhD, Professor of Psychiatry and Director of the Mount Sinai Alzheimer's Disease Research Center, latrepirdine showed significant and sustained improvement in cognitive behavior in Alzheimer's patients with minimal side effects. However, when the drug was tested in the U.S. in a Phase III trial, it did not demonstrate any improvement in people … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson's diseases

Phoenix benefits mishap vexes veterans

Posted: Published on August 13th, 2012

by Ken Alltucker - Aug. 12, 2012 09:08 PM The Republic | azcentral.com The federal agency that handles veterans benefits in Phoenix bungled nearly half the temporary-disability, traumatic-brain-injury and herbicide-exposure claims that were examined during a recent audit. The Veterans Benefits Administration office in Phoenix mishandled 47 percent of the claims in those three areas, according to a limited audit by the agency's inspector general issued last month. The mishandled claims frustrate veterans who must wait an average of nearly one year before the Phoenix office decides whether they are eligible for compensation. The Phoenix office has a backlog of more than 22,700 claims, with an average wait of 360 days before the cases are decided. Veterans organizations say the report illustrates the challenges that both returning soldiers and veterans face when attempting to secure a timely and accurate decision on benefits for disabilities. "This is something we have been struggling with for a very long time," said Tom Tarantino, chief policy officer at Iraq and Afghanistan Veterans of America. "The disability evaluation system was obsolete even before the Iraq and Afghanistan (wars)." The inspector general audit represented just a fraction of the total cases handled by the Phoenix office, … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Phoenix benefits mishap vexes veterans

Adam Lewis Considers Link Between Chronic Pain and Emotion

Posted: Published on August 13th, 2012

JACKSON, MS--(Marketwire -08/13/12)- Injuries and other health conditions have long been known to spark chronic pain; however, chronic pain does not always develop in people who sustain the same injuries or suffer from the same health conditions. A new report, published in Nature Neuroscience, asserts that emotional behavior may be involved in the onset of chronic pain. An article released by U.S. News further considers this possibility, which is rooted in neurological activity. Neurosurgeon Adam Lewis believes that this study is valuable in that it sheds light on how attention to emotional factors can assist in alleviating chronic pain through the right treatment options. The article asserts that the brain regions concerned with emotional and motivational behavior show higher levels of communication in patients who suffer from chronic pain. "For the first time, we can explain why people who may have the exact same initial pain either go on to recover or develop chronic pain," explains A. Vania Apkarian, one of the authors of the study and a professor at Northwestern University Feinberg School of Medicine. "The injury by itself is not enough to explain the ongoing pain. It has to do with the injury combined with the state of … Continue reading →

Posted in MS Treatment | Comments Off on Adam Lewis Considers Link Between Chronic Pain and Emotion

Epazz Has Completed Acquisition of MS Health Software

Posted: Published on August 13th, 2012

CHICAGO, Aug. 13, 2012 /PRNewswire/ -- Epazz, Inc., (EPAZ) a leading provider of cloud based business software solutions announced that it has acquired MS Health, a New Jersey based company. MS Health, mental health software, is a cloud based solution for Behavioral healthcare, mental health, and social services providers nationwide. MS Health CMHCi provides tools to manage, bill, and track behavioral healthcare and social services. With CMHCi, health care providers will realize the benefits of increased efficiency, accountability, and productivity. MS Health unaudited revenue for 2011 was over $450,000. "We are excited that MS Health has joined the Epazz family of cloud software products. We are currently combining MS Health into BoxesOS, our flagship cloud solution, to immediately provide MS Health customers with scalable cloud platform. Once this is complete, 'our per customer' revenue is expected to increase due to the enhanced function of BoxesOS," says Shaun Passley, CEO of Epazz Inc. CMHCi offers server based, internet, and secure cloud computing allowing you to access your information as you require. By maintaining a complete electronic client record, including data collection and reporting across multiple programs, locations, episodes of care, and service providers, CMHCi helps eliminate redundant record keeping. The scheduler … Continue reading →

Posted in MS Treatment | Comments Off on Epazz Has Completed Acquisition of MS Health Software

Three Continents, One Gene: DNA Detectives Track Down Nerve Disorder Cause

Posted: Published on August 13th, 2012

Gene mutation responsible of inherited ataxia found through sophisticated genetic analysis of Asian, European & American families Newswise ANN ARBOR, Mich. A global hunt for the cause of a crippling inherited nerve disorder has found its target. The discovery opens the door for better diagnosis and treatment of this particular disease but also for better understanding of why nerves in the brains movement-controlling center die, and how new DNA-mapping techniques can find the causes of other diseases that run in families. In a new paper in the Annals of Neurology, a team from Taiwan, France and the University of Michigan Health System report that mutations in the gene KCND3 were found in six families in Asia, Europe and the United States that have been haunted by the same form of a disease called spinocerebellar ataxia or SCA. The disease causes progressive loss of balance, muscle control and ability to walk. The new paper finds the disease gene in a region of chromosome 1 where a Dutch group had previously shown linkage with a form of SCA called SCA19, and the Taiwanese group on the new paper had shown similar linkage in a family for a form of the disease that … Continue reading →

Comments Off on Three Continents, One Gene: DNA Detectives Track Down Nerve Disorder Cause

Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories …

Posted: Published on August 13th, 2012

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies and CNS therapeutics, announced that Rasheda Ali Walsh, daughter of the legendary Muhammad Ali, visited the Companys laboratories as well as its cleanrooms at Hadassah Medical Center, where she received a briefing on the companys clinical trial conducted there. Ms. Ali Walsh, an internationally known advocate for promoting research and awareness of neurodegenerative diseases, is a member of the Advisory Board of BrainStorm. BrainStorms President, Mr. Chaim Lebovits, and CEO Dr. Adrian Harel accompanied Ms. Ali Walsh for a meeting with Prof. Dimitrios Karussis, Principal Investigator of the Companys ongoing Phase I/II clinical trial at Hadassah, and Prof. Tamir Ben-Hur, Head of the Neurology Department. The group discussed the latest innovative treatments for neurodegenerative diseases and BrainStorms leading role in this area. Having heard so much about the recent positive interim safety report and the outstanding progress being made by BrainStorm at Hadassah, I felt the need to actually meet the team in person, commented Ms. Ali. The amazing work being done here gives a ray of hope to patients and families worldwide that autologous stem cell transplants may be the … Continue reading →

Posted in Stem Cell Research | Comments Off on Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories …

1DegreeBio Launches Online Resource for Stem Cell Researchers

Posted: Published on August 13th, 2012

Toronto, ON (PRWEB) August 13, 2012 1DegreeBio Inc. today launched its Stem Cell Portal, where stem cell researchers can find antibodies and product data specific to their research. The portal also provides a venue where scientists can read and submit reviews of these products, and see quality ratings from the community. The portal is the second in a series of 1DegreeBio portals targeted at specific research areas which will be released in the coming year, and follows the June launch of the 1DegreeBio Epigenetics Portal. 1DegreeBio is the largest independent review website for custom research services, antibodies and related life science products. Stem cells are an extremely promising avenue in medical research, with new breakthroughs every day, said Alex Hodgson, Managing Director, 1DegreeBio. 1DegreeBio is excited to provide a free, specialized resource to support stem cell researchers, and help them find the best products for their work. Commercial antibodies are often an essential component in stem cell research, but inconsistency in antibody quality often slows the research process. The new 1DegreeBio Stem Cell Portal is designed to address this issue, as researchers can find validation data and community reviews of stem cell antibodies, helping them identify the right product for … Continue reading →

Posted in Stem Cell Research | Comments Off on 1DegreeBio Launches Online Resource for Stem Cell Researchers

Page 6,604«..1020..6,6036,6046,6056,606..6,6106,620..»